BMS sues Mylan to block Reyataz generic
20-03-2015
clu / iStockphoto.com
Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Bristol-Myers Squibb, Pfizer, Abbreviated New Drug Application, US District Court for the District of Delaware, generics
